- Conditions
- Photodamaged Skin, Volume Deficiency of the Midface
- Interventions
- Sculptra and Alastin Restorative Skin Complex, Sculptra and CeraVe Daily Moisturizing Lotion
- Combination Product
- Lead sponsor
- Galderma R&D
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 90
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Sensoril®, Placebo
- Drug
- Lead sponsor
- K.N. Roy Chengappa
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Cancer Patients on Active Surveillance
- Interventions
- Poly-ICLC intramuscular (IM) injection, Poly-ICLC, Intertumoral (IT) injection
- Drug
- Lead sponsor
- Ashutosh Kumar Tewari
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Chronic Rhinosinusitis (Diagnosis), Allergic Rhinosinusitis, Chronic Eosinophilic Rhinosinusitis
- Interventions
- Mometasone Furoate Nasal Irrigation, Mometasone Nasal Spray
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- St Louis, Missouri
- Conditions
- Dry Eye
- Interventions
- Brimonidine, Brimonidine Mono Therapy, sodium carboxymethylcellulose, Corticosteroid Eye Drop
- Drug
- Lead sponsor
- Ocugen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Hoffman Estates, Illinois • Yorkville, Illinois • Salt Lake City, Utah
- Conditions
- Healthy
- Interventions
- Emulsifier-containing diet
- Other
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Subjects
- Interventions
- Polymer based lubricating liquid, Moi-Stir
- Device
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
- Interventions
- Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab
- Biological · Drug · Radiation
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Fallopian Tube Carcinoma, Ovarian Carcinoma, Primary Peritoneal Carcinoma
- Interventions
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Epacadostat, Laboratory Biomarker Analysis, Pharmacological Study, Poly ICLC
- Biological · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Dry Eye Syndrome
- Interventions
- Glycerin and Polysorbate 80 based artificial tear, Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear, Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Metastatic Colon Cancer, Solid Tumor
- Interventions
- pembrolizumab, Poly-ICLC
- Drug
- Lead sponsor
- Asha Nayak
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Venous Leg Ulcer
- Interventions
- Marine polysaccharide dressing, Carboxymethylcellulose dressing
- Device
- Lead sponsor
- Medline Industries
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 5
- States / cities
- Fresno, California • Selma, California • Boston, Massachusetts + 2 more
- Conditions
- Adult Brain Glioblastoma, Glioblastoma Multiforme
- Interventions
- SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
- Drug
- Lead sponsor
- Stemline Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
- Conditions
- Rotator Cuff Tears, Rotator Cuff Tendinitis, Rotator Cuff Impingement, Injections, Glucocorticoids
- Interventions
- FX006 Injection
- Drug
- Lead sponsor
- Northwell Health
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Great Neck, New York
- Conditions
- Medication Adherence, HIV
- Interventions
- dolutegravir oral tablet 50mg, emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg, tenofovir disoproxil fumarate oral tablet 300mg, lamivudine oral tablet 300mg
- Drug
- Lead sponsor
- Rhonda Brand
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Dry Eye Syndromes
- Interventions
- Carboxymethylcellulose Sodium Based Eye Drops, Systane® Gel Drops, Genteal® Lubricant Gel Drops
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Azusa, California
- Conditions
- Hypertension
- Interventions
- NEO40 Daily
- Dietary Supplement
- Lead sponsor
- Hypertension Institute, Nashville
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diffuse Hemispheric Glioma, H3 G34-Mutant
- Interventions
- Biospecimen Collection, Dendritic Cell Therapy, Leukapheresis, Magnetic Resonance Imaging, Poly ICLC
- Procedure · Biological · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Recurrent Glioblastoma
- Interventions
- Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration, Poly ICLC
- Biological · Other · Drug
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Healthy Subjects
- Interventions
- Polymer based lubricating liquid
- Device
- Lead sponsor
- Procter and Gamble
- Industry
- Eligibility
- 18 Years to 40 Years · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
- Interventions
- MEK162
- Drug
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
- Conditions
- Partial-thickness Skin Donor Sites
- Interventions
- Altrazeal, Aquacel Ag
- Device
- Lead sponsor
- ULURU Inc.
- Industry
- Eligibility
- 3 Years to 85 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Adhesions, Cesarean Section, Delivery, Obstetric
- Interventions
- modified sodium hyaluronic acid and carboxymethylcellulose, Placebo
- Device
- Lead sponsor
- Winthrop University Hospital
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 753 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2014
- U.S. locations
- 3
- States / cities
- Mineola, New York • Stony Brook, New York • Allentown, Pennsylvania
- Conditions
- Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation
- Interventions
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis, Poly ICLC
- Biological · Drug · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Buffalo, New York